Umoja Biopharma

This past weekend, our incredible Team Umoja showed up in force for the BStrong Ride & Obliteride — biking, volunteering, and raising funds to Leave Cancer Behind. 🚴♀️💛 Whether on a bike or lending a helping hand, Umojians brought the same spirit they bring to work every day — making a Meaningful Impact while finding Joy in the journey. Here’s to making a difference, one ride (and one smile) at a time. #obliteride #bstrongride #curecancerfaster

Pride is both celebration and a reflection of the inclusive culture we’re building every day. At Umoja Biopharma, we believe inclusion fuels innovation and joy brings us together. This #Pride month, our teams in Seattle and Colorado hosted vibrant, joyful celebrations that honored our LGBTQIA+ colleagues and allies. Being unified in purpose means fostering a culture of belonging for everyone on our teams. Happy Pride month from all of us at Umoja! 🏳️🌈

Over the coming months, our team at Umoja Biopharma is gearing up for several scientific and industry events, where we’ll be sharing more about the story of our groundbreaking work on in vivo CAR T cell therapies:   🔸Tomorrow – Our CEO Andy Scharenberg joins University of Pennsylvania School of Medicine's Cellicon Valley meeting to discuss in vivo CAR Ts 🔸May 6 – Umoja CTO Ryan Crisman will speak at the virtual National Cancer Institute (NCI)'s In Vivo Conference 🔸May 13 - 17 – Catch our team at American Society of Gene & Cell Therapy 2025 in New Orleans for our poster presentation and industry panels 🔸May 15 – We join an in vivo CAR T industry panel at the PEGS Engineering Summit in Boston 🔸June 18 – Ryan Crisman returns for the Biotechnology Innovation Organization BIO panel on in vivo CAR Ts in Boston   We look forward to connecting with colleagues, collaborators, and innovators across the biotech community in the weeks to come.   We’re proud to be at the forefront of developing the industry’s first in vivo cell therapies. Visit our website to learn more: https://lnkd.in/geQ-9rFz

We are honored to have been nominated in GeekWire's Health Innovations of the Year category. Umoja Biopharma is proud to be a key part of the biotech ecosystem in Seattle as a clinical-stage leader of the in vivo CAR T cell movement, all with the hope of improving the reach, effectiveness, and patient access of CAR T cell therapies. Company summaries and voting are open at the link below, and we look forward to seeing many of our local friends and colleagues at the GeekWire awards on April 30th!

Congratulations to our co-founder Ryan Crisman on his selection to the Board of Directors of the Colorado BioScience Association. CBSA has been an exceptional local partner for our Louisville team as we took our CLIMB facility from initial ideation through what it is today: a site with global reach that is generating GMP drug product for our clinical trials and future patients.

Last week, we were excited to welcome 29 talented high school juniors to our Louisville Colorado facility for an inspiring Pathways in Technology Early College (P-TECH) day. Our team had the privilege of showing these budding scientists how our core values of joyfulness and making a meaningful impact come together in our daily mission of changing the future of how we treat cancer. Our own Kate Knights said "P-TECH is an incredible opportunity that I wish I had when I was in high school. The connection that students and industry mentors build is such a powerful resource to help them navigate their future. The internships they participate in with P-TECH help open their eyes to the work force that few others at their age get to experience. It is truly an astounding program to be a part of and see grow over the last five years." Through P-TECH's public-private partnership model, we are excited to welcome four of these promising students this summer for internships, continuing our commitment to nurturing the next generation of scientific talent. A big thank you to the Colorado BioScience Institute for this opportunity!

At Umoja Biopharma, we are proud to celebrate International Day of Women and Girls in Science by sharing stories from some of our own remarkable women here at Umoja. The beginning of a career dedicated to scientific curiosity can often be a memorable experience. At Umoja, that experience for Kristen Mittelsteadt, PhD included monitoring salmon development in 6th grade. For Kacie Breeding, it was a Systems Physiology class that revealed how bodies tell stories. To the next generation of women scientists, our team offers wisdom from their own experiences. Sarah Gould says, "Find your community, those who believe in your potential. Your ideas and contributions matter, your voice matters." Susana Hernandez also shared that "being a Mexican immigrant and a mother of two," she "aims to challenge stereotypes and open doors for future generations, particularly those from underserved communities." At Umoja, we're harnessing the power of the immune system to fight cancer, but we're also fostering an environment where diverse perspectives drive our innovation. Today and every day, we celebrate the women who have made and continue to make our mission possible.

We are excited to welcome Dr. Luke Walker as Chief Medical Officer of Umoja! Dr. Walker brings more than 20 years of hematology and clinical development experience to the role, and will be responsible for the leadership of Umoja’s clinical, regulatory, and medical functions, including our two clinical stage in vivo CAR T cell programs UB-VV111 and UB-VV400 in B cell malignancies. Full details: https://lnkd.in/eCcy35-y

This morning we announced a $100M Series C fundraise to support the continued development of our in vivo CAR T cell therapy pipeline, including our lead CD22 candidate UB-VV400. Full details are below, and please join us at the J.P. Morgan Healthcare Conference tomorrow for more details: https://lnkd.in/ggSHXXqM

Please join us at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday next week. Our co-founder and CEO Andy Scharenberg will share updates and progress of our in vivo CAR T cell programs as part of a catalyst-rich 2025 and beyond. https://lnkd.in/g_WiupxP